Welcome to our dedicated page for NUNZIA PHARMACEUTICL news (Ticker: NUNZ), a resource for investors and traders seeking the latest updates and insights on NUNZIA PHARMACEUTICL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NUNZIA PHARMACEUTICL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NUNZIA PHARMACEUTICL's position in the market.
Nunzia Pharmaceutical Corporation (OTC: NUNZ) is launching a patented Blood Warmer through its Medical Supply division. This FDA-approved device aims to combat hypothermia by preheating IV fluids prior to infusion. The global blood warmers market is projected to grow significantly, valued at USD 869.2 million in 2020 with an expected CAGR of 8.3% from 2021 to 2028. Additionally, Nunzia’s nutraceutical treatment for anxiety disorders, particularly ASD, shows promise with approximately 80% patient improvement within 24 to 96 hours. The market for ASD therapies could reach $4.6 billion by 2026.
Nunzi Pharmaceutical Corporation (OTC:NUNZ) entered a License Agreement with Michael Mitsunaga, granting exclusive rights to an IV Blood Warming System designed to prevent hypothermia in medical settings. The portable, FDA-approved product operates between 37°C and 44°C, ensuring safe IV fluid warming. Nunzi also offers NUNZIA, a unique nutraceutical supplement for anxiety disorders, particularly Autism Spectrum Disorder (ASD), demonstrating an 80% patient improvement rate. The ASD treatment market is projected to reach $4.6 billion by 2026, enhancing Nunzi's growth potential.
FAQ
What is the market cap of NUNZIA PHARMACEUTICL (NUNZ)?
